Abstract
Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK1 receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK1 receptor in anxiety and depression. The distribution of SP and the NK1 receptor in brain areas implicated in anxiety and depression is initially reviewed. This is followed by evaluation of the preclinical data obtained for SP and NK1 receptor antagonists in behavioral models of depression as well as the phenotype of genetically modified animals lacking the genes encoding for the NK1 receptor or for SP. The weight of the evidence supports antidepressant and anxiolytic activity of NK1 receptor antagonists. However, many of the studies do not control for nonspecific effects of the compounds, and when enantiomers that lack activity at the NK1 receptor are included, the results, in some cases, suggest that blockade of NK1 receptors does not account for the observed behavioral activity. Finally, clinical studies in depressed patients assessing SP levels in plasma and cerebrospinal fluid as well as the effect of NK1 receptor antagonists are reviewed. The clinical studies are a mixture of positive, failed and negative studies on the antidepressant activity of NK1 receptor antagonists, not unlike the early clinical results obtained with selective serotonin reuptake inhibitors.
Keywords: substance p, nk receptor, depression, anxiety, clinical studies
Current Pharmaceutical Design
Title: Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
Volume: 11 Issue: 12
Author(s): S. McLean
Affiliation:
Keywords: substance p, nk receptor, depression, anxiety, clinical studies
Abstract: Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK1 receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK1 receptor in anxiety and depression. The distribution of SP and the NK1 receptor in brain areas implicated in anxiety and depression is initially reviewed. This is followed by evaluation of the preclinical data obtained for SP and NK1 receptor antagonists in behavioral models of depression as well as the phenotype of genetically modified animals lacking the genes encoding for the NK1 receptor or for SP. The weight of the evidence supports antidepressant and anxiolytic activity of NK1 receptor antagonists. However, many of the studies do not control for nonspecific effects of the compounds, and when enantiomers that lack activity at the NK1 receptor are included, the results, in some cases, suggest that blockade of NK1 receptors does not account for the observed behavioral activity. Finally, clinical studies in depressed patients assessing SP levels in plasma and cerebrospinal fluid as well as the effect of NK1 receptor antagonists are reviewed. The clinical studies are a mixture of positive, failed and negative studies on the antidepressant activity of NK1 receptor antagonists, not unlike the early clinical results obtained with selective serotonin reuptake inhibitors.
Export Options
About this article
Cite this article as:
McLean S., Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?, Current Pharmaceutical Design 2005; 11 (12) . https://dx.doi.org/10.2174/1381612053764779
DOI https://dx.doi.org/10.2174/1381612053764779 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Pathophysiology of Tension-Type Headache: Potential Drug Targets
CNS & Neurological Disorders - Drug Targets Impact of COVID-19 Infection on Maternal and Neonatal Outcomes: A Review of 11078 Pregnancies Reported in the Literature
Current Women`s Health Reviews Therapeutic Potential of 5-HT7 Receptors in Mood Disorders
Current Drug Targets GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets Trends in the Pharmacology of Inflammatory and Allergic Eye Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design Antinociceptive Effects of Aza-Bicyclic Isoxazoline-Acylhydrazone Derivatives in Different Models of Nociception in Mice
Current Topics in Medicinal Chemistry Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Purinergic Signalling and Endothelium
Current Vascular Pharmacology Sequential Therapy For Helicobacter pylori in Elderly Patients: Effectiveness, Safety and Predictors of Success
Letters in Drug Design & Discovery Delirium in Older Patients – A Review
Current Psychiatry Reviews Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews